Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Protagonist Therapeutics, Inc. (PTGX)

Nasdaq Health Care Biotechnology S&P SmallCap 600
$132.04
-3.22 (-2.38%)
Close of Nov 06, 2026 · end-of-day data
Source: Protagonist Therapeutics, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 09, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$20.06M$30.93M$231.00K$28.63M$27.36M$26.58M$60.00M$434.43M$46.02M
Research & development$46.18M$59.50M$65.00M$74.51M$126.01M$126.22M$120.16M$138.13M$159.29M
Operating income-$37.90M-$42.27M-$80.52M-$64.52M-$125.84M-$131.37M-$93.65M$252.84M-$158.13M
Interest expense——$169.00K$598.00K—————
Pre-tax income-$36.96M-$39.72M-$77.88M-$64.84M-$125.55M-$127.39M-$78.95M$279.41M-$129.31M
Income tax$0-$799.00K-$691.00K$1.30M$0$0$0$4.22M$838.00K
Net income-$36.96M-$38.92M-$77.19M-$66.15M-$125.55M-$127.39M-$78.95M$275.19M-$130.15M
EBITDA-$37.49M-$41.74M-$79.79M-$63.57M-$125.03M-$130.34M-$92.67M$253.67M-$156.85M
EPS (basic)$-2.09$-1.74$-2.98$-1.92$-2.71$-2.60$-1.39$4.47$-2.05
EPS (diluted)$-2.09$-1.74$-2.98$-1.92$-2.71$-2.60$-1.39$4.23$-2.05
Diluted shares17.69M22.36M25.89M34.40M46.32M49.04M56.76M65.08M63.57M
Operating margin-188.9%-136.7%-34857.6%-225.4%-460.0%-494.2%-156.1%58.2%-343.6%
Net margin-184.2%-125.9%-33414.3%-231.1%-458.9%-479.3%-131.6%63.3%-282.8%

Balance sheet

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$106.03M$82.23M$33.01M$117.36M$123.67M$125.74M$186.73M$97.25M$128.39M
Short-term investments—$46.62M$100.01M$188.45M$203.24M$111.61M$154.89M$321.66M$438.97M
Total current assets$150.95M$137.50M$145.31M$315.61M$340.74M$243.08M$355.58M$591.64M$577.57M
Total assets$163.73M$139.47M$154.92M$324.47M$347.69M$247.93M$357.95M$744.73M$668.19M
Total current liabilities$42.55M$26.16M$35.41M$40.24M$44.02M$31.18M$21.27M$47.40M$45.44M
Long-term debt——$9.79M——————
Total debt——$9.79M——————
Total liabilities$43.10M$26.96M$74.95M$44.86M$47.67M$32.32M$21.27M$69.43M$53.48M
Shareholders' equity$120.63M$112.52M$79.96M$279.61M$300.02M$215.61M$336.68M$675.29M$614.71M

Cash flow

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$3.87M-$49.95M-$41.53M-$72.48M-$107.86M-$108.14M-$70.24M$184.15M$57.67M
Capital expenditures$666.00K$486.00K$967.00K$471.00K$1.10M$795.00K$609.00K$1.35M$1.59M
Free cash flow$3.21M-$50.43M-$42.49M-$72.95M-$108.97M-$108.93M-$70.84M$182.80M$56.08M
Investing cash flow$15.82M$2.21M-$53.71M-$90.97M-$15.86M$91.47M-$39.26M-$299.48M-$49.33M
Financing cash flow$65.55M$24.11M$46.04M$247.63M$129.92M$18.84M$170.48M$25.85M$22.86M
Stock-based compensation$4.24M$6.92M$8.35M$7.90M$16.39M$24.20M$29.29M$37.55M$45.97M
Depreciation & amortization$406.00K$527.00K$732.00K$948.00K$813.00K$1.03M$977.00K$826.00K$1.28M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.